Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...

Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...

Last year, the EPA issued a final rule that would limit emissions of ethylene oxide, a cancer-causing gas used to sterilize ...

Medtech company Globus Medical has expanded its spine portfolio by launching its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous ...

OsteoCentric Technologies has entered into a non-exclusive licensing agreement with Globus Medical.  OsteoCentric’s MIS Bone Preservation Tapping Technology & Instant Interlocking Thread-form is the ...

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...